WallStSmart

Perspective Therapeutics Inc. (CATX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 4013927% more annual revenue ($35.48B vs $884,000). MDT leads profitability with a 13.0% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 56/100 (C).

CATX

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 3.31

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CATX.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$86.58

$62.24 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CATX3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.3110/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

CATX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$507.00M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-41.6%2/10

ROE of -41.6% — below average capital efficiency

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : CATX

The strongest argument for CATX centers on Debt/Equity, Altman Z-Score, Price/Book.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : CATX

The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

CATX carries more volatility with a beta of 1.80 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (56/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Perspective Therapeutics Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Perspective Therapeutics Inc. is an innovative biotechnology company specializing in the development of next-generation radiopharmaceuticals designed to treat various types of cancer. Utilizing cutting-edge radioisotope technologies, the company aims to enhance the efficacy of cancer treatments, thereby improving patient outcomes in a rapidly evolving market for targeted therapies. With a strong leadership team and strategic partnerships, Perspective Therapeutics is well-equipped to advance its mission and deliver breakthrough solutions that address the growing need for effective cancer interventions.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?